| Send2Press.com • Today is Monday, February 13, 2012 | A Member of the Neotrope News Network |  |
|
|
NEWS ARCHIVES : U.S. and World News :
Medical :
Biotechnology
News
|
Press Release:
Epeius Biotechnologies Establishes Corporate Headquarters in San Marino, California - Facilities Include a Clinical Research Unit Dedicated to Evaluating New Genetic Medicine for Cancer
 Rexin-G(TM) is currently in clinical trials for metastatic pancreatic cancer at Mayo Clinic, Rochester, Minnesota, USA and is available for all solid tumors through an expanded access program in Manila, Philippines. The new headquarters in San Marino is located on the prestigious Huntington Drive and will integrate corporate offices, medical laboratories, and a Clinical Research Unit in appealing garden setting. *(Photo Caption: Artist rendering of proposed renovated San Marino headquarters.) Founded in the year 2000 by an inspired physician and an intrepid biophysicist at the University of Southern California, Epeius Biotechnologies consolidates a decade of biomedical research that began with gene discovery at Childrens Hospital Los Angeles, was translated into medical delivery at the USC Keck School of Medicine, progressed to clinical development at the USC Norris Comprehensive Cancer Center, and conducted landmark clinical trials as a freestanding biopharmaceutical company.  In a statement to the press, Dr. Erlinda Maria Gordon, M.D., founder and Chairman of the Board stated: "In the years to come, we hope and expect that the scientific and clinical accomplishments of Epeius Biotechnologies Corporation will become a source of pride and joy for the entire San Marino community."For more information about Epeius Biotechnologies Corporation visit: http://www.epeiusbiotech.com
NEWS SOURCE: Epeius Biotechnologies Corporation
Send2Press® is the originating wire service for this story. Terms of Use. © Epeius Biotechnologies Corporation. All trademarks acknowledged.
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Epeius Biotechnologies Corporation), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Journalist Resources:
Download original press release as issued including media contact information for Epeius Biotechnologies Corporation.
Additional News Releases on Similar Topics:
|
Subscribe to Send2Press®
Daily News Releases by E-Mail
Follow Send2Press on Social Sites: 
Additional News from
Epeius Biotechnologies Corporation : » Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy
|
||||||||||||||||||||||||||
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
|
Terms of Use and License
This "article format" version of the issued press release is Copr. © 1983-2012 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story (may not be posted on ANY site selling/offering SEO or PR services, newswire services, or adult content!). |
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: Epeius Biotechnologies Establishes Corporate Headquarters in San Marino, California - Facilities Include a Clinical Research Unit Dedicated to Evaluating New Genetic Medicine for Cancer, Rexin-G, Dr. Frederick L. Hall, Epeius, Biotech, Dr. Erlinda Maria Gordon, M.D., Clinical Research Unit, innovative anti-cancer agent, specialty pharmaceutical company, Orphan Drug Status by the FDA, New Genetic Medicine for Cancer research, , press release, Apr 4, 2006. |
|
THIS PAGE MEDIA READS (by media and public, as of today): 6950 times (1 today, 1 this week, 11 this month, 35 this year)
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)